New insider Bpifrance Sa claimed ownership of 10,898,595 units of Ordinary Shares (SEC Form 3)
$DBVT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 03/27/2025 |
3. Issuer Name and Ticker or Trading Symbol
DBV Technologies S.A. [ DBVT ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Ordinary Shares | 10,672,462(1) | I | By Bpifrance Participations S.A. |
| Ordinary Shares | 226,133(2) | I | By Innobio FPCI |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Warrants (right to buy) | 04/07/2025 | 04/07/2027 | Ordinary Shares | 6,556,781(1) | (3) | I | By Bpifrance Participations S.A. |
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
|
| Explanation of Responses: |
| 1. Bpifrance Participations S.A. ("Bpifrance Participations") directly owns the reported shares. Bpifrance Participations is a subsidiary owned at 99.99% by Bpifrance S.A. ("Bpifrance"). Bpifrance is jointly owned by Caisse des Depots et Consignations ("CDC") at 49.2% and EPIC Bpifrance ("EPIC") at 49.2%. CDC and EPIC jointly control Bpifrance. |
| 2. Innobio FPCI ("Innobio") directly owns the reported shares. Innobio is a fund managed by Bpifrance Investissement S.A.S. ("Bpifrance Investissement"), a subsidiary owned at 100% by Bpifrance Participations. Bpifrance Investissement may be deemed the beneficial owner of the reported shares, through its management of Innobio. |
| 3. The exercise of one warrant will give the right to subscribe to 1.75 ordinary shares at a price of (euro)1.5939 per warrant. |
| /s/ Sophie Paquin, Director of Legal Affairs, Bpifrance Participations S.A. | 04/07/2025 | |
| /s/ Laurence Giraudon, Chief Operating Officer, Finance and Operations Department, Asset Management Division, Caisse des Depots | 04/07/2025 | |
| /s/ Boubakar Dione, Group Director of Legal Affairs, Bpifrance S.A. | 04/07/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||